Welcome to our dedicated page for Kymera Therapeutics SEC filings (Ticker: KYMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kymera Therapeutics filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company developing oral small molecule degraders through targeted protein degradation. Its Form 8-K reports cover material events such as operating and financial results, clinical and regulatory disclosures, Regulation FD presentations, collaboration-related updates, and capital-raising arrangements involving common stock.
Proxy and governance filings describe shareholder voting matters, executive compensation, equity awards, board oversight, and bylaw provisions, including forum-selection language. The filing record also identifies KYMR common stock and recurring disclosure areas tied to the company’s pipeline, financing capacity, corporate governance, and public-company reporting obligations.
Morgan Stanley Smith Barney LLC reports Rule 144 notices of proposed sales of Common Stock by Jeremy Chadwick under pre-arranged 10b5-1 plans. The excerpt lists multiple sale dates in March–April 2026 with individual share counts and gross proceeds per transaction.
Kymeta Therapeutics, Inc. reported proposed and recent transactions involving Common Stock. The filing lists shares acquired upon vesting of Restricted Stock Units on 05/22/2026 and multiple 10b5-1 sales by Jeremy Chadwick between 03/02/2026 and 04/22/2026, with individual sale sizes shown in the excerpt.
The excerpt shows specific sale entries such as 91,250 shares on 03/23/2026 and other transactions ranging from 300 to 91,250 shares, with associated gross proceeds listed for many trades.
Kymera Therapeutics director Pamela Esposito exercised stock options to acquire 1,000 shares of Common Stock at an exercise price of $31.20 per share. After the transaction, she held 1,000 Common shares directly and 9,000 stock options with a $31.20 exercise price expiring on June 18, 2034. The filing notes that the shares underlying this option grant are fully vested and exercisable.
Kymera Therapeutics, Inc. Chief Financial Officer Bruce N. Jacobs exercised stock options to acquire 15,000 shares of common stock at an exercise price of $2.08 per share. Following this transaction, he directly holds 247,588 shares of common stock and 12,653 stock options that remain outstanding and expire on August 28, 2029.
Kymera Therapeutics: T. Rowe Price Investment Management, Inc. reports beneficial ownership of 5,460,257 shares of common stock, equal to 6.7% as of 03/31/2026. The filing "hereby declares and affirms that the filing of shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied."
The filing lists sole voting power of 5,318,875 shares and sole dispositive power of 5,460,257 shares. The signature block is dated 05/15/2026.
Kymera Therapeutics, Inc. Schedule 13G/A amendment shows Wellington group entities reporting shared beneficial ownership of 3,889,687 shares, representing 4.76% of common stock as of 03/31/2026. The filing attributes voting and dispositive power to multiple Wellington affiliates and states these shares are owned of record by clients of Wellington investment advisers.
The cover pages list shared voting power of 3,543,178 shares and shared dispositive power of 3,889,687. Signatures by a Compliance Manager are dated 05/15/2026.
Kymera Therapeutics director Elena Ridloff reported an exercise-and-sale transaction in company stock. She exercised stock options for 3,000 shares of common stock at $31.20 per share and sold 3,000 shares in an open-market transaction at $87.00 per share. Following these trades, her direct common stock holdings reported in this filing are zero, while 13,000 stock options remain outstanding and exercisable, expiring on June 17, 2034. The filing notes that these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan dated December 11, 2025, indicating they were scheduled in advance.
KYMR submitted a Form 144 reporting a proposed sale of 3,000 common shares tied to an exercise of stock options on 05/11/2026, with settlement indicated as cash and Morgan Stanley Smith Barney LLC listed in the securities table.
The filing also lists prior 10b5-1 sales by Elena Ridloff: 4,600 shares on 04/01/2026 for $392,921.88 and 7,400 shares on 03/31/2026 for $631,738.74.
Kymera Therapeutics ownership update: institutional investor FMR LLC reports beneficial ownership of 11,681,450.45 shares of Common Stock, representing 14.3% of the class. The filing lists sole voting power of 11,666,707 and sole dispositive power of 11,681,450.45, with an exhibit referencing a 13d-1(k) agreement.
Kymera Therapeutics reported higher collaboration revenue and a wider loss for the quarter ended March 31, 2026. Collaboration revenue rose to $34.4 million, driven by recognition of deferred revenue from its Gilead CDK2 partnership, while the company recorded a net loss of $69.2 million and basic and diluted net loss per share of $0.71.
Total operating expenses increased to $118.5 million, led by research and development spending of $98.2 million as multiple programs advance. Kymera ended the quarter with $1.55 billion in cash, cash equivalents and marketable securities and $1.54 billion of stockholders’ equity, providing substantial funding for its clinical-stage targeted protein degradation pipeline.
The company’s Sanofi IRAK4 collaboration did not contribute revenue this quarter after prior milestones, while Gilead collaboration revenue fully relieved related deferred revenue. After quarter-end, Gilead exercised its option to exclusively license KT-200, triggering a $45 million milestone expected to be recognized as second-quarter 2026 revenue.